



March 11, 2014

Mylan Introduces Critical Care Segment in India

Company launches anti-fungal AmBisome® as one of the segment's first product offerings

MUMBAI, India and PITTSBURGH, March 11, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched a Critical Care segment in India. The new segment focuses on anti-fungal, antibiotics and anti-coagulant therapies. AmBisome®, a leading anti-fungal, is one of the first critical care products Mylan is offering. Critical care is a leading therapeutic category in India, with \$2.6 billion* in annual sales.¹

Mylan CEO Heather Bresch commented, "The introduction of Mylan's Critical Care segment represents another milestone in the expansion of our commercial presence in India and supports our mission to expand access to high quality medicine around the world. Moreover, the Critical Care segment allows us to better satisfy the unmet medical needs of patients living with life-threatening diseases. The bacterial disease burden in India is among the highest in the world² and as a result, critical care medicines play an increasingly important role in limiting morbidity and mortality."

Bresch continued, "As an indicator of disease burden, pneumonia causes an estimated 410,000 deaths in India each year.² Many of these deaths occur because patients do not have access to life-saving antibiotics. We look forward to playing a central role in expanding access to affordable, quality medicine that these individuals desperately need."

Mylan President Rajiv Malik added, "This new segment further diversifies our product offerings in India. In the past 18 months alone, we have delivered on our commitment to providing high quality medicine to patients in India through the introduction of four unique and innovative segments - Antiretroviral, Women's Care, Oncology and, now, Critical Care. We are pleased to offer AmBisome as one of our first critical care products, and we look forward to introducing several more high-growth critical care products, including high-end antibiotics, in the near future."

AmBisome treats life-threatening, systemic fungal infections and the parasitic disease visceral leishmaniasis. The product is the innovator brand of Liposomal Amphotericin B and is widely accepted by hematologists, oncologists and intensivists for the treatment of suspected or definitive systemic fungal infections.

This press release includes statements that constitute "forward-looking statements," including with regard to the company's future growth and performance. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the impacts of competition; changes in economic and financial conditions of the company's business; uncertainties and matters beyond the control of management; and the other risks detailed in the company's filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,300 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. Mylan.com

*1 USD = 56 INR

1. IMS TSA JAN 2014
2. Global Antibiotic Resistance Partnership (GARP) - India Working Group

SOURCE Mylan Inc.

News Provided by Acquire Media